Table 3.
Factors associated with attrition.
| Short reference | Flannery et al. [31] | Gomez de Liano Lista et al. [51] | Gomez de Liano Lista et al. [51] |
|---|---|---|---|
| Attrition type | 1L chemo → 2L | 1L IO → 2L | 2L IO → 3L |
| Geographic location | USA | European countries | European countries |
| Study period | 2010–2016 | 2013–2017 | 2013–2017 |
| Older age | ✓ p < 0.005 |
✓ NS |
✓ NS |
| Poor ECOG PS | ✓ p < 0.005 |
— | — |
| Non-White race | ✓ NS |
— | — |
| Female sex | ✓ p < 0.005 |
✓ NS |
✓ NS |
| Poor renal function | ✓ p < 0.005 |
— | — |
| Primary organ being bladder | — | ✓ NS |
✓ NS |
| Comorbidities | — | — | — |
| Metastatic disease | — | — | ✓ p < 0.05 |
| Number of metastatic sites | ✓ NS |
✓ NS |
✓ p < 0.05 |
| Higher stage at initial diagnosis | ✓ NS |
✓ p < 0.05 |
✓ NS |
1L: First line; 2L: Second line; 3L: Third line; ECOG PS: Eastern Cooperative Oncology Group performance status; IO: Immunotherapy; NS: Not significant.